FDA OKs Amitiza for treatment of IBS-C

Apr 30, 2008

The U.S. Food and Drug Administration announced approval of Amitiza (lubiprostone) to treat constipation associated with irritable bowel syndrome.

The FDA said it approved Amitiza for use by adult women aged 18 and over, making the drug the only FDA-approved treatment for IBS-C available in the United States.

Irritable bowel syndrome is a characterized by cramping, abdominal pain, bloating, constipation and diarrhea. It causes a great deal of discomfort and distress to its sufferers, but affects at least twice as many women as men.

"For some people IBS can be quite disabling, making it difficult for them to fully participate in everyday activities," said Dr. Julie Beitz, director of the FDA's Office of Drug Evaluation III. "This drug represents an important step in helping to provide medical relief from their symptoms."

The efficacy of Amitiza in men wasn't conclusively demonstrated for IBS-C and the drug isn't approved for use by children or men. The FDA said it also approved Amitiza for the treatment of chronic idiopathic constipation.

Amitiza is manufactured by Sucampo Pharmaceuticals of Bethesda, Md., and Takeda Pharmaceuticals America Inc. of Deerfield, Ill.

Copyright 2008 by United Press International

Explore further: FDA: generic copaxone approved for multiple sclerosis

Related Stories

US govt sued over sea turtles snared in shrimp nets

2 hours ago

Tens of thousands of endangered sea turtles die every year in the United States when they are inadvertently snared in shrimp nets, an environmental group alleges, filing a lawsuit Wednesday against the government.

EU alleges Google's abuses hurt consumers, innovation

3 hours ago

The European Union's escalating legal attack on Google is likely to ignite a debate about whether the Internet search leader makes life more convenient for consumers or abuses its power to squeeze out rivals ...

Space open for business, says Electron launch system CEO

3 hours ago

Space, like business, is all about time and money, said Peter Beck, CEO of Rocket Lab, a US company with a New Zealand subsidiary. The problem, he added, is that, in cost and time, space has remained an incredibly ...

EU action on Google marks divergence with Washington

3 hours ago

The EU antitrust complaint filed Wednesday against Google represents a sharp divergence with Washington, which dropped a similar investigation two years ago, citing a lack of evidence against the Internet ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.